Keyword: Shionogi

The White House asked the FDA to clear Avigan for COVID-19. FTC delays forced Aurobindo and Novartis to end generics deal. China's API output dropped.

A new study showing that the flu can become resistant to Roche's Xofluza may affect efforts to get the drug approved in the U.S. to treat children.

Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.

AZ and Daiichi's antibody-drug conjugate nabs FDA priority review; FDA shames Torrent for tainted heart drugs; Takeda sells emerging markets drugs.

The Novartis unit pivoting toward complex generics and biosims has licensed a newly approved branded med, Shionogi's constipation drug Symproic.

Gilead oncology EVP Riva joins Glenmark spinoff as CEO; Biocon's biosimilar plant dinged by FDA; Shionogi licenses Akili's digital therapeutics.

AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.

Roche’s Xofluza has yet to see widespread uptake in the U.S., and new reports of resistance in Japan won’t help the drug’s case.